Search

Purpose: The purpose of this paper is to fabricate the scaffolds with different pore architectures using additive manufacturing and analyze its mechanical and biological properties for bone tissue engineering applications. Design/methodology/approach: The polylactic acid (PLA)/composite filament were fabricated through single screw extrusion and scaffolds were printed with four different pore architectures, i.e. circle, square, triangle and parallelogram with fused deposition modelling. Afterwards, scaffolds were coated with hydroxyapatite (HA) using dip coating technique. Various physical and thermo-mechanical tests have been conducted to confirm the feasibility. Furthermore, the biological tests were conducted with MG63 fibroblast cell lines to investigate the biocompatibility of the developed scaffolds. Findings: The scaffolds were successfully printed with different pore architectures. The pore size of the scaffolds was found to be nearly 1,500 µm, and porosity varied between 53% and 63%. The fabricated circular pore architecture resulted in highest average compression strength of 13.7 MPa and modulus of 525 MPa. The characterizations showed the fidelity of the work. After seven days of cell culture, it was observed that the developed composites were non-toxic and supported cellular activities. The coating of HA made the scaffolds bioactive, showing higher wettability, degradation and high cellular responses. Originality/value: The research attempts highlight the development of novel biodegradable and biocompatible polymer (PLA)/bioactive ceramic (Al2O3) composite for additive manufacturing with application in the tissue engineering field. [ABSTRACT FROM AUTHOR]

The chemotherapeutic potential of ruthenium(II) complexes has recently attracted researchers' interest as antibacterial and anticancer agents. In this study, two novel half-sandwich imine-based Ru complexes ([Ru(p-cymene)Cl(L-1)][PF6] (Ru-1) and [Ru(p-cymene)Cl(L-2)][PF6] (Ru-2)) were reported for their deoxyribonucleic acid (DNA) binding and antitubercular, antibacterial, and anticancer activities. The molecular structure of Ru-2 was obtained by single-crystal X-ray crystallography. DNA interaction studies were conducted by UV-Vis absorbance and fluorescence spectral titration which gave rise to DNA binding constants (Kb) of 1.32 × 106 and 1.82 × 106 for Ru-1 and Ru-2, respectively and the Stern–Volmer binding constant (KSV) values for Ru-1 and Ru-2 were 1.7763 × 104 M−1 and 7.6 × 103 M−1, respectively. The in vitro antitubercular activity was evaluated against Mycobacterium tuberculosis H37Ra. The antibacterial potential of both the Ru-complexes was examined against Gram-negative (Escherichia coli and Pseudomonas aeruginosa) and Gram-positive (Staphylococcus aureus and Bacillus subtilis) bacteria. The half-maximal inhibitory concentration (IC50) values for the antitubercular activity of Ru-1 and Ru-2 were 4.87 ± 1.32 μM and 5.78 ± 0.54 μM, respectively. A cytotoxic study of these complexes was performed against the human breast cancer cell line (MCF-7) and the human embryonic kidney cell line (HEK293) (normal cells). The study revealed meaningful activity of the Ru-1 complex against (cancer) MCF-7 cells, while the viability of HEK293 (normal) cells in the presence of Ru-2 was higher as compared to a reference drug 5FU. We suggest that these kinds of Ru-complexes could have potential for application in metallopharmaceuticals. [ABSTRACT FROM AUTHOR]

[Display omitted] • pH-sensitive biocompatible paclitaxel loaded multifunctional nanosystem was formulated. • The in vitro drug release profile results demonstrated a faster paclitaxel release from the nanosystem at pH 5.0 compared to pH 7.4. • FA binding to the folate receptor in cancer cells facilitated better targeted delivery. • Combination of paclitaxel and metal oxide nanoparticle provide a novel approach for cancer treatment. Multifunctional nanoplatforms as nanocarriers have attracted the interest of many scientists because they can achieve greater therapeutic effect in anticancer drug delivery to tumors with potential to improve cancer treatment, while currently available therapies are nonspecific and ineffectual. In present study, notable cancer therapeutic strategy which combines PEG functionalized poly (3-hydroxybutyric acid-co-hydroxyvaleric acid) (PHBV) nanospheres decorated with folic acid for delivery of paclitaxel (PTX) drug conjugated with copper oxide (CuO) nanoparticles (NPs) is proposed. Moreover, PTX loading with CuO NPs in PHBV nanosphere was done to increase its solubility and analyze its apoptotic effects in human breast cancer (MCF-7) cells. The pH-sensitive CuO-PTX@PHBV-PEG-FA nanosystem was successfully developed, as evidenced by number of characterizations. Resultant CuO-PTX@PHBV-PEG-FA NPs were 148.93 ± 10.5 nm in size, having 0.206 PDI, with −20.3 ± 0.6 mV zeta potential. MTT assay in MCF-7 cells was used to assess cell viability, while anticancer potential of CuO-PTX@PHBV-PEG-FA nanosystem was confirmed through different staining techniques. According to in vitro studies, FA-conjugated PHBV modified CuO-PTX targeted nanoparticles exhibited higher anticancer effect than free PTX probably due to binding interaction of folate receptor with cells that overexpress the target. This nanosystem has the potential to be a promising breast cancer treatment agent. [ABSTRACT FROM AUTHOR]

The chemotherapeutic potential of ruthenium(II) complexes has recently attracted researchers' interest as antibacterial and anticancer agents. In this study, two novel half-sandwich imine-based Ru complexes ([Ru( p -cymene)Cl(L-1)][PF 6 ] (Ru-1) and [Ru( p -cymene)Cl(L-2)][PF 6 ] (Ru-2)) were reported for their deoxyribonucleic acid (DNA) binding and antitubercular, antibacterial, and anticancer activities. The molecular structure of Ru-2 was obtained by single-crystal X-ray crystallography. DNA interaction studies were conducted by UV-Vis absorbance and fluorescence spectral titration which gave rise to DNA binding constants ( K b ) of 1.32 × 10 6 and 1.82 × 10 6 for Ru-1 and Ru-2, respectively and the Stern-Volmer binding constant ( K SV ) values for Ru-1 and Ru-2 were 1.7763 × 10 4 M -1 and 7.6 × 10 3 M -1 , respectively. The in vitro antitubercular activity was evaluated against Mycobacterium tuberculosis H37Ra. The antibacterial potential of both the Ru-complexes was examined against Gram-negative ( Escherichia coli and Pseudomonas aeruginosa ) and Gram-positive ( Staphylococcus aureus and Bacillus subtilis ) bacteria. The half-maximal inhibitory concentration (IC 50 ) values for the antitubercular activity of Ru-1 and Ru-2 were 4.87 ± 1.32 μM and 5.78 ± 0.54 μM, respectively. A cytotoxic study of these complexes was performed against the human breast cancer cell line (MCF-7) and the human embryonic kidney cell line (HEK293) (normal cells). The study revealed meaningful activity of the Ru-1 complex against (cancer) MCF-7 cells, while the viability of HEK293 (normal) cells in the presence of Ru-2 was higher as compared to a reference drug 5FU. We suggest that these kinds of Ru-complexes could have potential for application in metallopharmaceuticals.